跳至主要内容
临床试验/NL-OMON24379
NL-OMON24379招募中不适用

Baclofen as relapse prevention in the treatment of Gamma-hydroxybutyrate (GHB) dependence: an open label study.

ijmegen Institute for Scientist-Practitioners in Addiction (NISPA)/ Mental Health Care and Addiction Services (GGZ Nederland)/National program Scoring Results0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • GHB dependence is the primary diagnosis, according to the DSM-IV criteria. Patients are between 18-65 years old and should be able to read and speak Dutch sufficiently

排除标准

  • Patients with any current physical or psychiatric safety concerns are excluded.
  • Exclusion criteria are:
  • - Presence of a somatic safety concerns. These include liver cirrhosis and impaired renal function (as indicated by aspartate aminotransferase (AST), alanine transaminase (ALT), or gamma-glutamyl transferase (GGT) level >3 times the upper limit of normal (ULN); bilirubin > ULN; serum creatinine > ULN) , unstable hypertension, diabetes mellitus, and seizure disorder, including well controlled cases, currently taking anticonvulsants, insulin, or oral hypoglycemic and pregnancy.

研究者

发起方
ijmegen Institute for Scientist-Practitioners in Addiction (NISPA)/ Mental Health Care and Addiction Services (GGZ Nederland)/National program Scoring Results

相似试验